About Us

Bringing Hope To Life

2012
2013
2014
2015
2016
2017
2018
2012
Nov.
  • Senhwa Biosciences, Inc. begins operation on Nov. 16, 2012.
    Senhwa had raised NTD$ 339 million in its first round of funding
2013
Apr.
  • Senhwa signed an Asset Purchase and Sale Agreement with the American biotechnology company.
  • Senhwa’s US subsidiary is foundedin April, 2013.
  • CX-5461: A phase I clinical trial in hematologic malignancies is initiated with Peter MacCallum Cancer Center (PMCC) in Australia.
Sept.
  • Senhwa completed its NTD$ 25 million fundraising
Nov.
  • Funded by New Taipei City Government grant
  • Senhwa completed its NTD$ 198 million fundraising.
2014
Feb.
  • CX-4945: The US FDA approves a phase I/II trial that used in Cholangiocarcinoma
Mar.
  • Senhwa and Development Center for Biotechnology (DCB) signed a Collaboration Agreement
Apr.
  • Senhwa qualified to regulations and investment incentives according to “Act For The Development Of Biotech And New Pharmaceuticals Industry” by Biotechnology and Pharmaceutical Industries Promotion Office, MOEA, Taiwan
  • Senhwa’s clinical partner Peter MacCallum Cancer Centre (PMCC) was invited and presented the results of CX-5461 in animal study at AACR Annual Meeting 2014.
Aug.
  • Senhwa completed its NTD$ 27.6 million fundraising.
Sept.
  • Senhwa won the silver prize of 2014 Taiwan Healthcare and Agricultural Biotech Industries Innovation and Excellence Awards.
Oct.
  • Senhwa completed its initial public offering of stock.
Dec.
  • Senhwa debuts on Taiwan's emerging stock market and begins trading under the ticker"6492.TT" on 4 Dec. 2014
  • An investigational new drug (IND) application was submitted to Korean Ministry of Food and Drug Safety (MFDS) for treatment of human Cholangiocarcinoma with CX-4945
2015
Jan.
  • CX-4945: Senhwa receives Korean MFDS approval to begin Phase I/II trial for Cholangiocarcinoma.
Sept.
  • Senhwa and Chaperone Therapeutics, Inc. enter into an exclusive license agreement focused on the development of CK2 inhibitor for the treatment of neurodegenerative diseases.
  • CX-5461 granted 2015 Canada SU2C-CBCF Dream Team Drug and funded for a total of CAD$ 9 Million over 4 years.
Oct.
  • CX-4945: Senhwa receives Taiwan FDA approval to begin Phase I/II trial for Cholangiocarcinoma.
Dec.
  • Senhwa’s clinical partner Peter MacCallum Cancer Centre (PMCC) published the study of CX-5461 combined with other drugs in treatment of Haematologic Malignancies in Clinical Cancer Research.
2016
Mar.
  • Senhwa enters into Clinical Trial Agreement with Canadian Cancer Trials Group (CCTG) for CX-5461 Phase I/II Study.
  • Health Canada approves Clinical Trial Application for Phase I/II Clinical Trial of CX-5461 in Solid Tumors and Breast Cancers.
Oct.
  • Senhwa filed an application with the Taiwan Stock Exchange to seek a primary listing on the main board.
Nov.
  • Senhwa filed a new patent application covering the use of CX-5461 in combination with PARP inhibitors, PI3K and immunotherapeutic agents.
  • CX-5461 shows a synergistic effect in prostate cancer cells when combined with targeted drug, and this data was published by Senhwa’s partner in Australia.
Dec.
  • US subsidiary appointed Dr. Lucas S. Chang as General Counsel
  • CX-4945 Phase I clinical trial results accepted for presentation at the 2017 ASCO Gastrointestinal Cancers Symposium
  • CX-4945 granted Orphan Drug Designation by the US FDA in Cholangiocarcinoma
2017
Jan.
  • Taipei Exchange board of directors approved listing application on the Exchange's Main Board
Feb.
  • US subsidiary promoted John Soong M.D., FCAP as Chief Medical Officer
  • The research of CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours was accepted and published in Nature Communications on 17th
Mar.
  • Senhwa held pre-TPEx-listing performance presentation on 17th
Apr.
  • Senhwa raised NT$1.4 billion ($45.5 million) through the sale of 8.5 million shares at NT$162 in an IPO
  • Senhwa completed IPO and began trading on the TPEx mainboard on 24th
Oct.
  • Registered Capital changed to NTD$743,456,200
2018
Jan.
  • Registered Capital changed to NTD$743,926,200
Apr.
  • Registered Capital changed to NTD$744,166,200
May.
  • PBTC and Senhwa sign cooperation agreement to develop CX-4945 for pediatric brain tumor treatment